Searched for: author:"Rijken, D.C."
(1 - 20 of 54)

Pages

document
Rijken, D.C. (author), Hoegee-de Nobel, E. (author), Jie, A.F.H. (author), Atsma, D.E. (author), Schalij, M.J. (author), Nieuwenhuizen, W. (author), TNO Kwaliteit van Leven (author)
Background: The development of global tests for the fibrinolytic capacity in blood is hampered by the low base-line fibrinolytic activity in blood, by the involvement of both plasmatic components and blood cells in the fibrinolytic system and by the loss of fibrinolytic activity as a result of the action of plasminogen activator inhibitor-1 (PAI...
article 2008
document
Guimarães, A.H.C. (author), Laurens, N. (author), Weijers, E.M. (author), Koolwijk, P. (author), van Hinsbergh, V.W.M. (author), Rijken, D.C. (author), TNO Kwaliteit van Leven (author)
OBJECTIVE - Besides having a key role in fibrinolysis, the plasminogen system has been implicated in cell migration and angiogenesis. A common mechanism is the binding of plasminogen to carboxy-terminal lysine residues in partially degraded fibrin or on cellular surfaces. Here we examined the involvement of thrombin activatable fibrinolysis...
article 2007
document
Guimarães, A.H.C. (author), van Tilburg, N.H. (author), Vos, H.L. (author), Bertina, R.M. (author), Rijken, D.C. (author)
Thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels exhibit a large interindividual variability in which genetic control seems to play a major role. However, recent reports have questioned the association between TAFI concentration and genotype, suggesting that variable antibody reactivity towards TAFI isoforms, particularly the...
article 2004
document
Rijken, D.C. (author), Barrett-Bergshoeff, M.M. (author), Jie, A.F.H. (author), Criscuoli, M. (author), Sakharov, D.V. (author), Gaubius Instituut TNO (author)
Amediplase (K2tu-PA) is a hybrid plasminogen activator, consisting of the kringle 2 domain of alteplase and the protease domain of urokinase. The objective of this study was to determine the in vitro clot penetration of amediplase in relation to its fibrin binding and to compare the properties with those of alteplase. The clot lysis activity of...
article 2004
document
Sakharov, D.V. (author), Jie, A.F.H. (author), Filippov, D.V. (author), Bekkers, M.E.A. (author), van Boom, J.H. (author), Rijken, D.C. (author), Gaubius Instituut TNO (author)
Extracellular matrix (ECM) of tissues, vascular tissue in particular, contains a high concentration of negatively charged glycosaminoglycans (GAGs), which are involved in the regulation of cell motility, cell proliferation and the regulation of enzyme activities. Previously, we have shown that the vascular ECM is capable of binding an extremely...
article 2003
document
Sakharov, D.V. (author), Jie, A.F.H. (author), Bekkers, M.E.A. (author), Emeis, J.J. (author), Rijken, D.C. (author), Gaubius Instituut TNO (author)
We present the first steps in the elaboration of an approach of extracellular matrix-targeted local drug delivery (ECM-LDD), designed to provide a high concentration, ubiquitous distribution, and long-term retention of a drug within the vessel wall after local intravascular delivery. The approach is based on the concept of a bifunctional drug...
article 2001
document
Sakharov, D.V. (author), Hekkenberg, R.T. (author), Rijken, D.C. (author), Gaubius Instituut TNO (author)
High-frequency ultrasound has been shown to accelerate enzymatic fibrinolysis. One of the supposed mechanisms of this effect is the enhancement of mass transport by acoustic streaming, i.e., ultrasound-induced macroscopic flow around the clot. In this study, which is aimed at further elucidating the mechanisms of the acceleration of fibrinolysis...
article 2000
document
Braat, E.A.M. (author), Jie, A.F.H. (author), Ronday, H.K. (author), Beekman, B. (author), Rijken, D.C. (author), Gaubius Instituut TNO (author)
Background - Excessive fibrin deposition within the inflamed joints of rheumatoid arthritis (RA) patients suggests that local fibrinolysis is inefficient, which seems to be in contrast with the observed increased levels of urokinase type plasminogen activator (u-PA). Thrombin-mediated inactivation of single chain u-PA (scu-PA) into an inactive...
article 2000
document
Braat, E.A.M. (author), Los, P. (author), Rijken, D.C. (author), Gaubius Instituut TNO (author)
Thrombin cleaves single-chain urokinase-type plasminogen activator (scu- PA) into a virtually inactive two-chain form (tcu-PA/T), a process which may contribute to the maintenance of a fresh blood clot. We have examined the inactivation of scu-PA by thrombin in a plasma milieu to get more insight in the physiological relevance of this phenomenon...
article 1998
document
van der Kaaden, M.E. (author), Rijken, D.C. (author), van Berkel, T.J.C. (author), Kuiper, J. (author), Gaubius Instituut TNO (author)
article 1998
document
Eam, B. (author), Dooijewaard, G. (author), Rijken, D.C. (author), Gaubius Instituut TNO (author)
Activated factor XII (FXIIa), the initiator of the contact activation system, has been shown to activate plasminogen in a purified system. However, the quantitative role of FXIIa as a plasminogen activator in (factor XH-dependent) fibrinolysis in plasma is still unclear. The aim of our study was to investigate plasminogen activator activity (PAA...
article 1998
document
Noorman, F. (author), Braat, E.A.M. (author), Barrett-Bergshoeff, M.M. (author), Barbé, E. (author), van Leeuwen, A. (author), Lindeman, J. (author), Rijken, D.C. (author), TNO Preventie en Gezondheid (author)
Recently we developed mouse monocloual antibodies (mAb) against the isolated human 175-kDa mannose receptor. In the present study we tested whether these mAb are suitable for the detection of the mannose receptor on cultured macrophages using flow cytometry and on cells in human tissues using immunohistochemistry. Human monocytes did not react...
article 1997
document
van der Kaaden, M.E. (author), Rijken, D.C. (author), Kruijt, J.K. (author), van Berkel, T.J.C. (author), Kuiper, J. (author), TNO Preventie en Gezondheid (author)
Urokinase-type plasminogen activator (u-PA) is used as a thrombolytic agent in the treatment of acute myocardial infarction. In vitro, recombinant single-chain u-PA (rscu-PA) expressed in E. coli is recognized by the Low-Density Lipoprotein Receptor-related Protein (LRP) on rat parenchymal liver cells. In this study we investigated the role of...
article 1997
document
Noorman, F. (author), Barrett-Bergshoeff, M.M. (author), Bekkers, M. (author), Emeis, J.J. (author), Rijken, D.C. (author), Gaubius Instituut TNO (author)
Dextran is used during surgery as a prophylactic agent to prevent deep venous thrombosis. Recently it has been shown that dextran increases t-PA plasma concentrations in patients. As dextran is a potential ligand for the mannose receptor, we studied whether this glucose-polymer would be able to inhibit mannose receptor-mediated clearance of t-PA...
article 1997
document
Sakharov, D.V. (author), Plow, E.F. (author), Rijken, D.C. (author), Gaubius Instituut TNO (author)
The precursor of plasma carboxypeptidase B (pCPB) also known as thrombin-activable fibrinolysis inhibitor can be converted by thrombin to an active enzyme capable of eliminating C-terminal Lys- and Arg-residues from proteins. The activation is about 1000-fold more efficient in the presence of thrombomodulin (TM). We investigated the...
article 1997
document
Barrett-Bergshoeff, M.M. (author), Moorman, F. (author), Bos, R. (author), Rijken, D.C. (author), Gaubius Instituut TNO (author)
To study the role of the mannose receptor in cellular uptake and degradation of tissue-type plasminogen activator (t-PA), a set of five monoclonal antibodies (Moab) was generated against the mannose receptor isolated from human placental tissue. All Moab specifically recognised the 175 kDa mannose receptor in a crude placenta extract, as shown...
article 1997
document
Sakharov, D.V. (author), Lijnen, H.R. (author), Rijken, D.C. (author), Gaubius Instituut TNO (author)
Staphylokinase (STA), a protein of bacterial origin, induces highly fibrin-specific thrombolysis both in human plasma in vitro and in pilot clinical trials. Using fluorescence microscopy, we investigated the spatial distribution of fluorescein isothiocyanate (FITC)-labeled STA during lysis of a plasma clot and its binding to purified fibrin...
article 1996
document
Rijken, D.C. (author), van der Kaaden, M.E. (author), Groeneveld, E. (author), Barrett-Bergshoeff, M.M. (author), van Thjc, B. (author), Kuiper, J. (author), Gaubius Instituut TNO (author)
Urokinase-type plasminogen activator (u-PA) is rapidly cleared from the circulation with a half-life of a few minutes. We have previously shown that non-glycosylated recombinant u-PA is recognized by LRP, whereas urinary u-PA is recognized by the asialoglycoprotein receptor (ASGPr) on liver parenchymal cells. In the present study we...
article 1996
document
Rijken, D.C. (author), Jie, A.F.H. (author), Gaubius Laboratory TNO Preventie en Gezondheid (author)
Reteplase is a protein consisting of the kringle-2 and protease domains of tissue-type plasminogen activator (t-PA). Because intravenous heparin will be used as an adjunct to thrombolytic therapy with reteplase, we investigated the interactions in vitro between heparin and reteplase as well as between heparin and recombinant t-PA (alteplase) as...
article 1996
document
Kuiper, J. (author), van Teijlingen, M. (author), Vietsch, H. (author), Rijken, D.C. (author), van Berkel, T.J.C. (author), Blessen, E.A.L. (author), Division of Biopharmaceutics, LACDR, Leiden, Netherlands Gaubius Laboratory TNO Preventie en Gezondheid (author)
A major complication of the use of of tissue-type plasminogen activator (t-PA) as fibrinolytic agent is its rapid clearance from the bloodstream. We have studied whether t-PA clearance can be reduced by preventing receptor-mediated endocytosis of t-PA in vivo via the mannose receptor and the low-density lipoprotein receptor related protein (LRP)...
article 1996
Searched for: author:"Rijken, D.C."
(1 - 20 of 54)

Pages